Market Research Logo

North America Infertility Testing And Treatment Market Forecast 2018-2026

NORTH AMERICA INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

KEY FINDINGS
The North America infertility testing and treatment market collected a net revenue of $6099.20 million in 2017. Over the forecasted period of 2018-2026, the market is expected to exhibit a CAGR of 6.07%, collecting a net total of $10326.86 million.

MARKET INSIGHTS
The North American region witnessed about 17% infertility cases due to male factors; while female factors were responsible only in 12% cases. However, rising use of contraceptive drugs is increasing infertility among the North American women. The U.S is the biggest market for infertility testing and treatment in this region, followed by Canada. It is estimated that up to 20% couples in Canada experience infertility to some extent. However, the cost of these infertility treatments varies across both these regions.

COMPETITIVE INSIGHTS
Progyny, Quest Diagnostic, Agilent, Illumina Inc, Andrology Solutions, Thermo Fisher Scientific Inc, Endo Pharmaceuticals, Elucigene, Natera Inc, Esco Micro Pte. Ltd, Ferring Pharmaceuticals, Vitrolife Ab, Integrated Genetics and, Roche are the noted companies in this market.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Ivf Dominates The Female Treatment Market
3.2.2. Oxidative Stress Analysis Is The Fastest Growing Male Infertility Testing Market
4. Market Overview
4.1. Market Definition
4.2. Market Drivers And Impact
4.2.1. Rise In Infertility And Treatment Awareness
4.2.2. Medical Tourism In Fertility Treatments
4.2.3. Surrogacy Laws Are Getting More Defined
4.2.4. Healthcare Advances Have Finetuned Fertility Treatment
4.2.5. Increasing Effectiveness Of Treatments
4.2.6. Healthier Donor Eggs
4.2.7. Introduction Of New Testing Devices
4.3. Restraints And Impact
4.3.1. Treatment Procedure Out Of Reach To Many Due To Costs Involved
4.3.2. Country-wise Regulatory Issues
4.4. Market Opportunities
4.4.1. Reducing The Cost Of Treatment To Make It More Accessible
4.4.2. Ivf Attracting Investments From Private Equity Investors
4.4.3. Diy Testing Increasing Access And Reducing Cost
4.5. Market Challenges
4.5.1. Infertility Considered A Social Taboo Amongst Men
4.5.2. Perils Of Multiple Pregnancies
4.5.3. Traditional Treatments Used Widely As An Alternative To Infertility Treatments
4.5.3.1. Diet And Supplements
4.5.3.2. Acupuncture
4.5.3.3. Therapy
4.5.3.4. Qigong
5. Infertility Causes
5.1. Causes Of Male Infertility
5.1.1. Abnormality In The Sperm
5.1.2. Environmental Factors
5.1.3. Poor Health And Lifestyle
5.2. Causes Of Female Infertility
5.2.1. Ovulation Disorders
5.2.2. Damage To Fallopian Tubes
5.3. Moral Questions
6. Male Infertility Testing And Treatment Market 2018-2026 ($ Million)
6.1. Market By Male Infertility Testing
6.1.1. Dna Fragmentation
6.1.2. Oxidative Stress Analysis
6.1.3. Sperm Penetration Assay
6.1.4. Computer Assisted Semen Analysis (Casa)
6.1.5. Sperm Agglutination
6.1.6. Microscopic Examination
6.1.7. Others
6.2. Market By Male Infertility Treatment
6.2.1. Vasovasostomy And Vasoepididymostomy (Vasectomy Reversal)
6.2.2. Sperm Retrieval Treatment
6.2.3. Microsurgical Sperm Aspiration (Mesa)
6.2.4. Testicular Sperm Extraction (Tese)
6.2.5. Varicocele Repairs
6.2.6. Assisted Reproductive Techniques (Art)
6.2.7. Intrauterine Insemination (Iui)
6.2.8. In Vitro Fertilization (Ivf)
6.2.9. Intracytoplasmic Sperm Injection (Icsi)
7. Female Infertility Testing And Treatment Market 2018-2026 ($ Million)
7.1. Market By Female Infertility Testing
7.1.1. Ovulation Testing
7.1.2. Hysterosalpingography
7.1.3. Laparoscopy
7.1.4. Transvaginal Ultrasound
7.1.5. Ovarian Reserve Testing
7.1.6. Hormonal Level Testing
7.1.7. Others (Genetic Testing)
7.2. Market By Female Infertility Treatment
7.2.1. In Vitro Fertilization
7.2.2. Intrauterine Insemination (Iui)
7.2.3. Drug And Hormone Therapies
8. North America Infertility Testing And Treatment Market By End-users 2018-2026 ($ Million)
8.1. Fertility And Surgical Centers
8.2. Hospitals And Research Laboratories
8.3. Cryobanks
9. Key Analytics
9.1. Porters 5 Force Model
9.1.1. Threat Of New Entrants
9.1.2. Threat Of Substitute Products
9.1.3. Bargaining Power Of Buyers
9.1.4. Bargaining Power Of Suppliers
9.1.5. Intensity Of Competitive Rivalry
9.2. Value Chain Analysis
9.2.1. Raw Material Procurement
9.2.2. Manufacturing
9.2.3. Supply Logistics
9.2.4. Distribution Channels
9.2.5. End Users
9.3. Key Buying Criteria
9.3.1. Treatment Options
9.3.2. Quality Of Medical Procedures
9.3.3. Price Of Treatments
9.3.4. Shift Towards Medical Tourism
9.3.5. Reimbursement
9.4. Regulatory Framework
9.5. Key Trends
9.5.1. Male Infertility Treatment Segment Is Rising
9.5.2. Fertility Tourism- An Important Trend
9.5.3. Upper Middle Income Group Is The Key Target
9.5.4. Regulatory Environment Key Market Enabler
9.5.5. More Couples Opting For Surrogacy
9.5.6. Technology Enabling The Success Of Fertility Treatments
9.6. Vendor Landscape
9.7. Opportunity Matrix
10. Key Analytics – Testing Market
10.1. Porters 5 Force Analysis
10.1.1. Threat Of New Entrants
10.1.2. Threat Of Substitute Products
10.1.3. Bargaining Power Of Buyers
10.1.4. Bargaining Power Of Suppliers
10.1.5. Intensity Of Competitive Rivalry
10.2. Key Buying Criteria
10.3. Vendor Landscape
10.4. Opportunity Matrix
11. North America Infertility Testing And Treatment Market Country Analysis 2018-2026 ($ Million)
11.1. Us
11.2. Canada
12. Competitive Analysis
12.1. Andrology Solutions
12.1.1. Overview
12.1.2. Product Portfolio
12.1.3. Scot Analysis
12.2. Endo Pharmaceuticals
12.2.1. Overview
12.2.2. Product Portfolio
12.2.3. Strategic Moves
12.2.4. Scot Analysis
12.3. Progyny
12.3.1. Overview
12.3.2. Product Portfolio
12.3.3. Strategic Moves
12.3.4. Scot Analysis
12.4. Ferring Pharmaceuticals
12.4.1. Overview
12.4.2. Product Portfolio
12.4.3. Strategic Moves
12.4.4. Scot Analysis
12.5. Genea
12.5.1. Overview
12.5.2. Product Portfolio
12.5.3. Strategic Moves
12.5.4. Scot Analysis
12.6. Halotech Dna
12.6.1. Overview
12.6.2. Product Portfolio
12.6.3. Strategic Moves
12.6.4. Scot Analysis
12.7. Irvine Scientific
12.7.1. Overview
12.7.2. Product Portfolio
12.7.3. Strategic Moves
12.7.4. Scot Analysis
12.8. Merck
12.8.1. Overview
12.8.2. Product Portfolio
12.8.3. Strategic Moves
12.8.4. Scot Analysis
12.9. Origio
12.9.1. Overview
12.9.2. Product Portfolio
12.9.3. Strategic Moves
12.9.4. Scot Analysis
12.10. Ovascience
12.10.1. Overview
12.10.2. Product Portfolio
12.10.3. Strategic Moves
12.10.4. Scot Analysis
12.11. Vitrolife Ab
12.11.1. Overview
12.11.2. Product Portfolio
12.11.3. Strategic Moves
12.11.4. Scot Analysis
12.12. Thermo Fisher Scientific Inc
12.12.1. Overview
12.12.2. Product Portfolio
12.12.3. Strategic Moves
12.12.4. Scot Analysis
12.13. The Cooper Companies, Inc
12.13.1. Overview
12.13.2. Product Portfolio
12.13.3. Strategic Moves
12.13.4. Scot Analysis
12.14. Quest Diagnostic
12.14.1. Overview
12.14.2. Product Portfolio
12.14.3. Scot Analysis
12.14.4. Strategic Moves
12.15. Esco Micro Pte. Ltd.
12.15.1. Overview
12.15.2. Product Portfolio
12.15.3. Strategic Moves
12.15.4. Scot Analysis
12.16. Elucigene
12.16.1. Overview
12.16.2. Product Portfolio
12.16.3. Scot Analysis
12.16.4. Strategic Initiative
12.17. Alere
12.17.1. Overview
12.17.2. Product Portfolio
12.17.3. Scot Analysis
12.17.4. Strategic Initiative
12.18. Celmatrix
12.18.1. Overview
12.18.2. Product Portfolio
12.18.3. Scot Analysis
12.18.4. Strategic Initiative
12.19. Veritas Genetics
12.19.1. Overview
12.19.2. Product Portfolio
12.19.3. Scot Analysis
12.19.4. Strategic Initiative
12.20. Claritas Genomics
12.20.1. Overview
12.20.2. Product Portfolio
12.20.3. Scot Analysis
12.20.4. Strategic Initiative
12.21. Roche
12.21.1. Overview
12.21.2. Product Portfolio
12.21.3. Scot Analysis
12.21.4. Strategic Initiative
12.22. Labcorp
12.22.1. Overview
12.22.2. Product Portfolio
12.22.3. Scot Analysis
12.22.4. Strategic Initiative
12.23. Agilent
12.23.1. Overview
12.23.2. Product Portfolio
12.23.3. Scot Analysis
12.23.4. Strategic Initiative
12.24. Integrated Genetics
12.24.1. Overview
12.24.2. Product Portfolio
12.24.3. Scot Analysis
12.25. Phosphorus Diagnostics
12.25.1. Overview
12.25.2. Product Portfolio
12.25.3. Scot Analysis
12.25.4. Strategic Initiative
12.26. Centogene
12.26.1. Overview
12.26.2. Product Portfolio
12.26.3. Scot Analysis
12.26.4. Strategic Initiative
12.27. Natera Inc
12.27.1. Overview
12.27.2. Product Portfolio
12.27.3. Scot Analysis
12.27.4. Strategic Initiative
12.28. Illumina Inc
12.28.1. Overview
12.28.2. Product Portfolio
12.28.3. Scot Analysis
12.28.4. Strategic Initiative

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report